Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

39 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Simultaneous targeting of EGFR, HER2, and HER4 by afatinib overcomes intrinsic and acquired cetuximab resistance in head and neck squamous cell carcinoma cell lines.
De Pauw I, Lardon F, Van den Bossche J, Baysal H, Fransen E, Deschoolmeester V, Pauwels P, Peeters M, Vermorken JB, Wouters A. De Pauw I, et al. Among authors: deschoolmeester v. Mol Oncol. 2018 Jun;12(6):830-854. doi: 10.1002/1878-0261.12197. Epub 2018 May 1. Mol Oncol. 2018. PMID: 29603584 Free PMC article.
Mutation analysis of genes in the EGFR pathway in Head and Neck cancer patients: implications for anti-EGFR treatment response.
Boeckx C, Weyn C, Vanden Bempt I, Deschoolmeester V, Wouters A, Specenier P, Van Laer C, Van den Weyngaert D, Kockx M, Vermorken JB, Peeters M, Pauwels P, Lardon F, Baay M. Boeckx C, et al. Among authors: deschoolmeester v. BMC Res Notes. 2014 Jun 4;7:337. doi: 10.1186/1756-0500-7-337. BMC Res Notes. 2014. PMID: 24899223 Free PMC article.
Overcoming cetuximab resistance in HNSCC: the role of AURKB and DUSP proteins.
Boeckx C, Op de Beeck K, Wouters A, Deschoolmeester V, Limame R, Zwaenepoel K, Specenier P, Pauwels P, Vermorken JB, Peeters M, Van Camp G, Baay M, Lardon F. Boeckx C, et al. Among authors: deschoolmeester v. Cancer Lett. 2014 Nov 28;354(2):365-77. doi: 10.1016/j.canlet.2014.08.039. Epub 2014 Sep 2. Cancer Lett. 2014. PMID: 25192874
Dual Targeting of Epidermal Growth Factor Receptor and HER3 by MEHD7945A as Monotherapy or in Combination with Cisplatin Partially Overcomes Cetuximab Resistance in Head and Neck Squamous Cell Carcinoma Cell Lines.
De Pauw I, Wouters A, Van den Bossche J, Deschoolmeester V, Baysal H, Pauwels P, Peeters M, Vermorken JB, Lardon F. De Pauw I, et al. Among authors: deschoolmeester v. Cancer Biother Radiopharm. 2017 Sep;32(7):229-238. Cancer Biother Radiopharm. 2017. PMID: 28910149
In vitro study of the Polo-like kinase 1 inhibitor volasertib in non-small-cell lung cancer reveals a role for the tumor suppressor p53.
Van den Bossche J, Deben C, De Pauw I, Lambrechts H, Hermans C, Deschoolmeester V, Jacobs J, Specenier P, Pauwels P, Vermorken JB, Peeters M, Lardon F, Wouters A. Van den Bossche J, et al. Among authors: deschoolmeester v. Mol Oncol. 2019 May;13(5):1196-1213. doi: 10.1002/1878-0261.12477. Epub 2019 Apr 5. Mol Oncol. 2019. PMID: 30859681 Free PMC article.
The radiosensitising effect of gemcitabine and its main metabolite dFdU under low oxygen conditions is in vitro not dependent on functional HIF-1 protein.
Wouters A, Pauwels B, Burrows N, Baay M, Deschoolmeester V, Vu TN, Laukens K, Meijnders P, Van Gestel D, Williams KJ, Van den Weyngaert D, Vermorken JB, Pauwels P, Peeters M, Lardon F. Wouters A, et al. Among authors: deschoolmeester v. BMC Cancer. 2014 Aug 16;14:594. doi: 10.1186/1471-2407-14-594. BMC Cancer. 2014. PMID: 25128202 Free PMC article.
39 results